본문 바로가기
KERD
논문KCI 등재

좌심실 수축 기능 저하 심부전증의 치료

Treatment of Heart Failure with Reduced Ejection Fraction: Current Update

최동주|박진주
대한내과학회 (The Korean Association Of Internal Medicine)|2015.02|대한내과학회지 (The Korean Journal of Medicine)|제88권 제2호|pp. 127-134|DOI http://dx.doi.org/10.3904/kjm.2015.88.2.127

2

조회

0

다운로드

5

인용

0

참고문헌

키워드

진료 지침Practice guidelineSystolic heart failure수축기 심부전
주제분류내과학

초록

박출률 저하 심부전증의 치료는 심부전의 병태생리적 기전이 점차 밝혀지면서 약물 및 비약물적 치료에서 눈부신발전을 보여 주었으며 심부전 환자의 치료 목표는 단순 증상 호전이 아니라 생존율 개선이다. 현재 많은 약제들이 임상시험을 통해 개발되고 있으며 이를 통해 심부전 환자의생존율이 개선될 것으로 기대된다. 이와 같은 상황에서 임상의는 약물적 요법의 장단점을 잘 이해하고 적절한 치료 방법을 선택해야 환자의 증상이 호전되고 생존율이 향상될 것이다.

Abstract

The prevalence of heart failure (HF) has been steadily increasing and it now creates an enormous social and economic burden. HF is a syndrome characterized by a high mortality rate, frequent hospitalization, a reduced quality of life, and a complex therapeuticregimen. In the last three decades, major progress in both the diagnosis and management of HF has taken place, and thepharmacologic and non-pharmacologic advances have led to a significant improvement in survival and symptoms in HF patients. After an accurate diagnosis, a proper HF management plan requires a multi-level team approach comprised of the correct combinationof drug therapy, device therapy, and surgery, including heart transplantation. In this review, we focused on the pharmacologicand non-pharmacologic treatment strategies for HF with reduced ejection fraction. The goal was to develop treatment guidelinesbased on significant evidence derived from large clinical trials.

참고문헌 (30)

  1. Writing Committee Members, "2013 ACCF", AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation, Circulation, pp.2013, 128[DOI]
  2. McMurray JJ, "ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC", Eur J Heart Fail, 14, pp.803~869 (2012)
  3. McKee PA, "The natural history of congestive heart failure: the Framingham study", N Engl J Med, 285, pp.1441~1446 (1971)
  4. Owan TE, "Trends in prevalence and outcome of heart failure with preserved ejection fraction", N Engl J Med, 355, pp.251~259 (2006)
  5. 유병수, "심부전의 약물 치료", 대한내과학회지, 81(6), pp.716~719 (2011), 대한내과학회
  6. "Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group", N Engl J Med, 316, pp.1429~1435 (1987)
  7. "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators", N Engl J Med, 325, pp.293~302 (1991)
  8. Yusuf S, "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators", N Engl J Med, 342, pp.145~153 (2000)
  9. Packer M, "Comparative effects of low and high doses of the angiotensinconverting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group", Circulation, 100, pp.2312~2318 (1999)
  10. Pitt B, "Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II", Lancet, 355, pp.1582~1587 (2000)
  11. Cohn JN, "Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure", N Engl J Med, 345, pp.1667~1675 (2001)
  12. McMurray JJ, "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial", Lancet, 362, pp.767~771 (2003)
  13. Mann JF, "Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial", Lancet, 372, pp.547~553 (2008)
  14. "The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial", Lancet, 353, pp.9~13 (1999)
  15. "Effect of metoprolol CR", XL in chronic heart failure: Metoprolol CR, Lancet, pp.1999, 353[DOI]
  16. Packer M, "Effect of carvedilol on survival in severe chronic heart failure", N Engl J Med, 344, pp.1651~1658 (2001)
  17. Packer M, "Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study", Circulation, 106, pp.2194~2199 (2002)
  18. Dargie HJ, "Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial", Lancet, 357, pp.1385~1390 (2001)
  19. Flather MD, "Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)", Eur Heart J, 26, pp.215~225 (2005)
  20. Funck-Brentano C, "Influence of order and type of drug (bisoprolol vs. enalapril)on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial", Eur J Heart Fail, 13, pp.765~772 (2011)
  21. Pitt B, "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators", N Engl J Med, 341, pp.709~717 (1999)
  22. Zannad F, "Eplerenone in patients with systolic heart failure and mild symptoms", N Engl J Med, 364, pp.11~21 (2011)
  23. Swedberg K, "Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study", Lancet, 376, pp.875~885 (2010)
  24. Digitalis Investigation Group, "The effect of digoxin on mortality and morbidity in patients with heart failure", N Engl J Med, 336, pp.525~533 (1997)
  25. Moss AJ, "Cardiac-resynchronization therapy for the prevention of heart-failure events", N Engl J Med, 361, pp.1329~1338 (2009)
  26. Cleland JG, "The effect of cardiac resynchronization on morbidity and mortality in heart failure", N Engl J Med, 352, pp.1539~1549 (2005)
  27. Barnard CN, "The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town", S Afr Med J, 41, pp.1271~1274 (1967)
  28. Stehlik J, "The registry of the International Society for Heart and Lung Transplantation:Twenty-eighth Adult Heart Transplant Report-2011", J Heart Lung Transplant, 30, pp.1078~1094 (2011)
  29. Mancini D, "Selection of cardiac transplantation candidates in 2010", Circulation, 122, pp.173~183 (2010)
  30. Deng MC, "Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity. Comparative Outcome and Clinical Profiles in Transplantation (COCPIT) Study Group", BMJ, 321, pp.540~545 (2000)

관련 논문AI추천

Update on heart failure management and future directions박명수, 윤종찬, 최홍미대한내과학회 · The Korean Journal of Internal Medicine2019 · 제34권 제1호심부전의 약물 치료유병수대한내과학회 · 대한내과학회지2011 · 제81권 제6호좌심실 수축 기능 보전 심부전증의 치료나수진, 백상홍대한내과학회 · 대한내과학회지2015 · 제88권 제2호Current status of heart failure: global and KoreaDong-Ju Choi, Jin Joo Park대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제3호급성 심부전의 혈역학적 감시와 치료박철수대한중환자의학회 · Acute and Critical Care2011 · 제26권 제1호새로운 심부전 약제, SGLT2 억제제조동혁대한내과학회 · 대한내과학회지2023 · 제98권 제2호

이 간행물의 다른 논문 (8건)

급성 심부전 증후군의 치료강석민pp. 121-126좌심실 수축 기능 보전 심부전증의 치료백상홍, 나수진pp. 135-141미세 먼지와 천식장안수pp. 150-155단일 간 종괴로 보여진 양성 림프구 과다 증식의 고주파 열치료강은규, 김민욱, 김정권, 김현수, 박서화pp. 177-181급성 심근경색으로 진단된 진성 적혈구 증가증 1예김혜미, 이학승, 정지현, 서정원, 김지혜pp. 192-196
원문 보기